<DOC>
	<DOC>NCT01224366</DOC>
	<brief_summary>To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Confirmed diagnosis of T2DM On a stable dose of insulin as defined by the protocol On a stable does of metformin (if applicable) as defined by the protocol Age 18 to 80 years HbA1c of 7.5 to 11.0% Body Mass Index (BMI) 22 to 40 kg/m2 Type 1 diabetes Shortacting or rapidacting insulin Pregnancy or lactation Evidence of serious diabetic complications Evidence of serious cardiovascular complications Laboratory value abnormalities as defined by the protocol Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Add-on to insulin</keyword>
</DOC>